Key Highlights

  • Second-quarter 2026 Revenue was USD 730,571, up 36.5% from USD 535,060 a year earlier.
  • Gross Margin widened to 41.7% from 30.5%.
  • The second-quarter net loss was USD 1,506,343 versus USD 840,933.
  • Cash was USD 4,546,140 at June 30, 2026, up from USD 1,025,987 at year-end 2025.
  • Reported stockholders' Equity of USD 1,620,700 sits below the USD 2,500,000 Nasdaq minimum.

What Moved 20/20 Biolabs Before the Open (up USD 0.0347, 14.77%)

20/20 Biolabs (NASDAQ:AIDX) was up USD 0.0347, or 14.77%, to USD 0.2696 in pre-market trading on November 4, 2026. No Earnings release or financing announcement dated November 2 to November 4, 2026 was identified, so the catalyst is only partly clear.

What the company has announced is an investor webinar on Wednesday, November 4, 2026, at 12:00 p.m. Eastern, according to a press release dated October 29, 2026. The CEO is expected to discuss the OneTest Franchise program, 2027 licensing plans, roll-up acquisitions, FDA and Medicare strategy and a Maryland firefighter cancer screening effort. The release said the webinar will not cover third-quarter financial results, and the company holds the session on the first Wednesday of each month.

Business Background and Recent Results

20/20 Biolabs develops and commercializes laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. OneTest for Cancer is a multi-cancer early detection test still in development toward FDA authorization, while OneTest for Longevity measures inflammatory biomarkers and is commercially available. Tests run in the company's CLIA-licensed laboratory in Gaithersburg, Maryland.

In the second quarter of 2026, revenue was USD 730,571, up 36.5%, with OneTest revenue up 47.1% and representing 95.3% of the total. Gross Profit rose to USD 304,727 from USD 163,264. Operating expenses grew to USD 1,548,950 from USD 1,008,935, which the company attributed mainly to Nasdaq listing costs and product development.

First-half revenue of USD 1,083,946 was roughly flat against USD 1,088,880, and the first-half net loss widened to USD 3,681,180 from USD 1,605,511. Loss per share was USD 0.26 for the quarter versus USD 0.17.

Plans, Balance Sheet and Risks

The company plans to license its protein tumor marker approach to clinical laboratories in 2027 under a royalty-based franchise model, although it described interest from regional laboratories as preliminary. It has also pointed to a statutory Medicare pathway for FDA-authorized multi-cancer tests beginning in 2028.

Common shares outstanding rose to 12,251,198 at June 30, 2026 from 5,442,249 at December 31, 2025, a dilution of more than 125% (calculated). The company also carries Series E convertible preferred stock with a Liquidation preference of USD 6,273,600.

Nasdaq notified the company on July 17, 2026 that its bid price was below USD 1.00, with a compliance deadline of January 13, 2027. A second notice on September 3, 2026 cited stockholders' equity of USD 1,620,700 against the USD 2,500,000 requirement, a shortfall of USD 879,300 (calculated). A plan was due about October 18, 2026, and failure to regain equity compliance would remove eligibility for an extra bid-price period.

At under USD 1, the shares are a penny stock, which typically brings sharp volatility, thin Liquidity and a meaningful risk of further dilution.

What to Watch Next

Investors will watch the webinar remarks, any update on the Nasdaq equity plan, the third-quarter Form 10-Q and further Capital raising. Franchise agreements and FDA progress would be the operational markers. Extended-hours moves in low-priced shares can reverse quickly once regular trading begins.